LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article: Adaptive platform trials using multi-arm, multi-stage protocols: getting fast answers in pandemic settings

    Noor, N. M. / Pett, S. L. / Esmail, H. / Crook, A. M. / Vale, C. L. / Sydes, M. R. / Parmar, M. K. B.

    Abstract: Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations Early work focused on rapid sequencing of severe acute respiratory ...

    Abstract Global health pandemics, such as coronavirus disease 2019 (COVID-19), require efficient and well-conducted trials to determine effective interventions, such as treatments and vaccinations Early work focused on rapid sequencing of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequent in-vitro and in-silico work, along with greater understanding of the different clinical phases of the infection, have helped identify a catalogue of potential therapeutic agents requiring assessment In a pandemic, there is a need to quickly identify efficacious treatments, and reject those that are non-beneficial or even harmful, using randomised clinical trials Whilst each potential treatment could be investigated across multiple, separate, competing two-arm trials, this is a very inefficient process Despite the very large numbers of interventional trials for COVID-19, the vast majority have not used efficient trial designs Well conducted, adaptive platform trials utilising a multi-arm multi-stage (MAMS) approach provide a solution to overcome limitations of traditional designs The multi-arm element allows multiple different treatments to be investigated simultaneously against a shared, standard-of-care control arm The multi-stage element uses interim analyses to assess accumulating data from the trial and ensure that only treatments showing promise continue to recruitment during the next stage of the trial The ability to test many treatments at once and drop insufficiently active interventions significantly speeds up the rate at which answers can be achieved This article provides an overview of the benefits of MAMS designs and successes of trials, which have used this approach to COVID-19 We also discuss international collaboration between trial teams, including prospective agreement to synthesise trial results, and identify the most effective interventions We believe that international collaboration will help provide faster answers for patients, clinicians, and health care systems around the world, including for future waves of COVID-19, and enable preparedness for future global health pandemics
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #2533
    Database COVID19

    Kategorien

  2. Article: Use of strategies to improve retention in primary care randomised trials: a qualitative study with in-depth interviews.

    Brueton, V C / Stevenson, F / Vale, C L / Stenning, S P / Tierney, J F / Harding, S / Nazareth, I / Meredith, S / Rait, G

    BMJ open

    2014  Volume 4, Issue 1, Page(s) e003835

    Abstract: Objective: To explore the strategies used to improve retention in primary care randomised trials.: Design: Qualitative in-depth interviews and thematic analysis.: Participants: 29 UK primary care chief and principal investigators, trial managers ... ...

    Abstract Objective: To explore the strategies used to improve retention in primary care randomised trials.
    Design: Qualitative in-depth interviews and thematic analysis.
    Participants: 29 UK primary care chief and principal investigators, trial managers and research nurses.
    Methods: In-depth face-to-face interviews.
    Results: Primary care researchers use incentive and communication strategies to improve retention in trials, but were unsure of their effect. Small monetary incentives were used to increase response to postal questionnaires. Non-monetary incentives were used although there was scepticism about the impact of these on retention. Nurses routinely used telephone communication to encourage participants to return for trial follow-up. Trial managers used first class post, shorter questionnaires and improved questionnaire designs with the aim of improving questionnaire response. Interviewees thought an open trial design could lead to biased results and were negative about using behavioural strategies to improve retention. There was consensus among the interviewees that effective communication and rapport with participants, participant altruism, respect for participant's time, flexibility of trial personnel and appointment schedules and trial information improve retention. Interviewees noted particular challenges with retention in mental health trials and those involving teenagers.
    Conclusions: The findings of this qualitative study have allowed us to reflect on research practice around retention and highlight a gap between such practice and current evidence. Interviewees describe acting from experience without evidence from the literature, which supports the use of small monetary incentives to improve the questionnaire response. No such evidence exists for non-monetary incentives or first class post, use of which may need reconsideration. An exploration of barriers and facilitators to retention in other research contexts may be justified.
    MeSH term(s) Communication ; Female ; Humans ; Interviews as Topic ; Male ; Motivation ; Patient Participation/statistics & numerical data ; Primary Health Care ; Qualitative Research ; Randomized Controlled Trials as Topic/methods ; Research Subjects/statistics & numerical data ; Surveys and Questionnaires
    Language English
    Publishing date 2014-01-24
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2599832-8
    ISSN 2044-6055
    ISSN 2044-6055
    DOI 10.1136/bmjopen-2013-003835
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.

    Vale, C L / Fisher, D J / White, I R / Carpenter, J R / Burdett, S / Clarke, N W / Fizazi, K / Gravis, G / James, N D / Mason, M D / Parmar, M K B / Rydzewska, L H / Sweeney, C J / Spears, M R / Sydes, M R / Tierney, J F

    Annals of oncology : official journal of the European Society for Medical Oncology

    2018  Volume 29, Issue 5, Page(s) 1249–1257

    Abstract: Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), ...

    Abstract Background: Our prior Systemic Treatment Options for Cancer of the Prostate systematic reviews showed improved survival for men with metastatic hormone-naive prostate cancer when abiraterone acetate plus prednisolone/prednisone (AAP) or docetaxel (Doc), but not zoledronic acid (ZA), were added to androgen-deprivation therapy (ADT). Trial evidence also suggests a benefit of combining celecoxib (Cel) with ZA and ADT. To establish the optimal treatments, a network meta-analysis (NMA) was carried out based on aggregate data (AD) from all available studies.
    Methods: Overall survival (OS) and failure-free survival data from completed Systemic Treatment Options for Cancer of the Prostate reviews of Doc, ZA and AAP and from recent trials of ZA and Cel contributed to this comprehensive AD-NMA. The primary outcome was OS. Correlations between treatment comparisons within one multi-arm, multi-stage trial were estimated from control-arm event counts. Network consistency and a common heterogeneity variance were assumed.
    Results: We identified 10 completed trials which had closed to recruitment, and one trial in which recruitment was ongoing, as eligible for inclusion. Results are based on six trials including 6204 men (97% of men randomised in all completed trials). Network estimates of effects on OS were consistent with reported comparisons with ADT alone for AAP [hazard ration (HR) = 0.61, 95% confidence interval (CI) 0.53-0.71], Doc (HR = 0.77, 95% CI 0.68-0.87), ZA + Cel (HR = 0.78, 95% CI 0.62-0.97), ZA + Doc (HR = 0.79, 95% CI 0.66-0.94), Cel (HR = 0.94 95% CI 0.75-1.17) and ZA (HR = 0.90 95% CI 0.79-1.03). The effect of ZA + Cel is consistent with the additive effects of the individual treatments. Results suggest that AAP has the highest probability of being the most effective treatment both for OS (94% probability) and failure-free survival (100% probability). Doc was the second-best treatment of OS (35% probability).
    Conclusions: Uniquely, we have included all available results and appropriately accounted for inclusion of multi-arm, multi-stage trials in this AD-NMA. Our results support the use of AAP or Doc with ADT in men with metastatic hormone-naive prostate cancer. AAP appears to be the most effective treatment, but it is not clear to what extent and whether this is due to a true increased benefit with AAP or the variable features of the individual trials. To fully account for patient variability across trials, changes in prognosis or treatment effects over time and the potential impact of treatment on progression, a network meta-analysis based on individual participant data is in development.
    MeSH term(s) Abiraterone Acetate/therapeutic use ; Androgen Antagonists/standards ; Androgen Antagonists/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/standards ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Disease Progression ; Disease-Free Survival ; Docetaxel/therapeutic use ; Humans ; Male ; Network Meta-Analysis ; Prednisolone/analogs & derivatives ; Prednisolone/therapeutic use ; Prednisone/therapeutic use ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/drug therapy ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology ; Zoledronic Acid/therapeutic use
    Chemical Substances Androgen Antagonists ; Docetaxel (15H5577CQD) ; Zoledronic Acid (6XC1PAD3KF) ; prednisolone acetate (8B2807733D) ; Prednisolone (9PHQ9Y1OLM) ; Prostate-Specific Antigen (EC 3.4.21.77) ; Abiraterone Acetate (EM5OCB9YJ6) ; Prednisone (VB0R961HZT)
    Language English
    Publishing date 2018-05-21
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Systematic Review
    ZDB-ID 1025984-3
    ISSN 1569-8041 ; 0923-7534
    ISSN (online) 1569-8041
    ISSN 0923-7534
    DOI 10.1093/annonc/mdy071
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Substantial improvement in UK cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit.

    Vale, C L / Tierney, J F / Davidson, S E / Drinkwater, K J / Symonds, P

    Clinical oncology (Royal College of Radiologists (Great Britain))

    2010  Volume 22, Issue 7, Page(s) 590–601

    Abstract: Aims: To compare survival and late complications between patients treated with chemoradiotherapy and radiotherapy for locally advanced cervix cancer.: Materials and methods: A Royal College of Radiologists' audit of patients treated with radiotherapy ...

    Abstract Aims: To compare survival and late complications between patients treated with chemoradiotherapy and radiotherapy for locally advanced cervix cancer.
    Materials and methods: A Royal College of Radiologists' audit of patients treated with radiotherapy in UK cancer centres in 2001-2002. Survival, recurrence and late complications were assessed for patients grouped according to radical treatment received (radiotherapy, chemoradiotherapy, postoperative radiotherapy or chemoradiotherapy) and non-radical treatment. Late complication rates were assessed using the Franco-Italian glossary.
    Results: Data were analysed for 1243 patients from 42 UK centres. Overall 5-year survival was 56% (any radical treatment); 44% (radical radiotherapy); 55% (chemoradiotherapy) and 71% (surgery with postoperative radiotherapy). Overall survival at 5 years was 59% (stage IB), 44% (stage IIB) and 24% (stage IIIB) for women treated with radiotherapy, and 65% (stage IB), 61% (stage IIB) and 44% (stage IIIB) for those receiving chemoradiotherapy. Cox regression showed that survival was significantly better for patients receiving chemoradiotherapy (hazard ratio=0.77, 95% confidence interval 0.60-0.98; P=0.037) compared with those receiving radiotherapy taking age, stage, pelvic node involvement and treatment delay into account. The grade 3/4 late complication rate was 8% (radiotherapy) and 10% (chemoradiotherapy). Although complications continued to develop up to 7 years after treatment for those receiving chemoradiotherapy, there was no apparent increase in overall late complications compared with radiotherapy alone when other factors were taken into account (hazard ratio=0.94, 95% confidence interval 0.71-1.245; P=0.667).
    Discussion: The addition of chemotherapy to radiotherapy seems to have improved survival compared with radiotherapy alone for women treated in 2001-2002, without an apparent rise in late treatment complications.
    MeSH term(s) Adolescent ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Neoplasms/mortality ; Bone Neoplasms/secondary ; Bone Neoplasms/therapy ; Brachytherapy ; Combined Modality Therapy ; Female ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/secondary ; Liver Neoplasms/therapy ; Lung Neoplasms/mortality ; Lung Neoplasms/secondary ; Lung Neoplasms/therapy ; Lymphatic Metastasis ; Medical Audit ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/therapy ; Neoplasm Staging ; Pelvic Neoplasms/etiology ; Pelvic Neoplasms/pathology ; Radiation Oncology ; Radiotherapy Dosage ; Survival Rate ; Survivors ; Treatment Outcome ; Uterine Cervical Neoplasms/mortality ; Uterine Cervical Neoplasms/pathology ; Uterine Cervical Neoplasms/therapy ; Young Adult
    Language English
    Publishing date 2010-07-01
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1036844-9
    ISSN 1433-2981 ; 0936-6555
    ISSN (online) 1433-2981
    ISSN 0936-6555
    DOI 10.1016/j.clon.2010.06.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Interlaboratory testing scheme designed as a clinical chemistry control procedure.

    Ellis, B C / Vale, C L / Petersen, R C / Poulter, B J

    Clinical chemistry

    1995  Volume 41, Issue 5, Page(s) 762–763

    MeSH term(s) Chemistry, Clinical/statistics & numerical data ; Humans ; Laboratories/statistics & numerical data ; Quality Control
    Language English
    Publishing date 1995-05
    Publishing country England
    Document type Letter
    ZDB-ID 80102-1
    ISSN 1530-8561 ; 0009-9147
    ISSN (online) 1530-8561
    ISSN 0009-9147
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top